CA 15-3: Uses and limitation as a biomarker for breast cancer
Top Cited Papers
- 1 December 2010
- journal article
- review article
- Published by Elsevier BV in Clinica Chimica Acta; International Journal of Clinical Chemistry
- Vol. 411 (23-24), 1869-1874
- https://doi.org/10.1016/j.cca.2010.08.039
Abstract
No abstract availableKeywords
This publication has 71 references indexed in Scilit:
- Mucins in cancer: function, prognosis and therapyNature Reviews Cancer, 2009
- International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent ChemotherapyJNCI Journal of the National Cancer Institute, 2009
- Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009Annals Of Oncology, 2009
- Direct Targeting of the Mucin 1 Oncoprotein Blocks Survival and Tumorigenicity of Human Breast Carcinoma CellsCancer Research, 2009
- Serum HER‐2/neu and relative resistance to trastuzumab‐based therapy in patients with metastatic breast cancerCancer, 2008
- Follow-up after breast cancerBMJ, 2008
- American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast CancerJournal of Clinical Oncology, 2007
- Monitoring different stages of breast cancer using tumour markers CA 15-3, CEA and TPAEuropean Journal Of Cancer, 2004
- Tumor Necrosis Factor-α Converting Enzyme/ADAM 17 Mediates MUC1 SheddingJournal of Biological Chemistry, 2003
- The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markersEuropean Journal Of Cancer, 1999